Cliona Rooney
Baylor College of Medicine
H-index: 117
North America-United States
Top articles of Cliona Rooney
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma | Helen Heslop Che-Hsing Li Sandhya Sharma Andras Heczey David Steffin | 2024/4/11 | |
Tunneling CARs: Gene modifications to enhance CAR-T infiltration into solid tumors | Cancer Research | Stacey N Van Pelt Bilal Omer Lindsay Talbot Cliona Rooney Rohan Fernandes | 2024/3/22 |
Methods of cell culture for adoptive cell therapy | 2024/1/4 | ||
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing | Cytotherapy | Paul Shafer Wingchi K Leung Mae Woods Jong Min Choi Carlos M Rodriguez-Plata | 2024/1/15 |
Process for T cell expansion | 2022/5/19 | ||
Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma | Blood Advances | Sandhya Sharma Naren U Mehta Tim Sauer Dirk P Dittmer Lisa A Rollins | 2024/4/19 |
PHASE 1/2 MULTICENTER CLINICAL TRIAL OF DONOR SPECIFIC TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION VIA ENGINEERED T CELLS WITH SUPPRESSING FUNCTIONS | Y Maehara K Uchida K Takeda K Okumura B Omer | 2023/11/1 | |
Abstract P6-10-11: Engineered neoantigen-specific T cell receptors to treat metastatic breast cancer | Cancer Research | Paul Shafer Wingchi K Leung Mae L Woods Carlos Rodriguez-Plata Arushana Ali | 2023/3/1 |
Overcoming the tumor microenvironment for cell therapy by targeting myeloid derived suppressor cells through a trail-r2 specific receptor | 2023/7/6 | ||
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target | Nature Cancer | Kamal Mandal Gianina Wicaksono Clinton Yu Jarrett J Adams Michael R Hoopmann | 2023/11 |
Generation of HPV-specific T-cells | 2023/2/28 | ||
Treatment and prevention of alloreactivity using virus-specific immune cells expressing chimeric antigen receptors | 2023/6/8 | ||
Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein–Barr Virus-Specific T-Cells | International Journal of Molecular Sciences | Sandhya Sharma Tim Sauer Bilal A Omer Thomas Shum Lisa A Rollins | 2023/10/31 |
Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies | David H Quach Premal Lulla Cliona M Rooney | 2023/2/23 | |
IMMU-15. PHASE I TRIAL OF GD2. CART-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR (C7R) FOR TREATMENT OF HIGH-GRADE PEDIATRIC CNS TUMORS | Neuro-Oncology | Frank Lin Austin Stuckert Candise Tat Karen Moeller Mark White | 2023/6/1 |
Treatment and prevention of cancer using virus-specific immune cells expressing chimeric antigen receptors | 2023/7/13 | ||
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy | Journal for Immunotherapy of Cancer | Sandhya Sharma Mae Woods Naren U Mehta Tim Sauer Kathan S Parikh | 2023 |
OFF‐THE‐SHELF CD30. CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30. CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL) | Hematological Oncology | CA Ramos DH Quach PD Lulla RH Rouce S Sharma | 2023/6 |
Longitudinal analysis of the evolution of cellular immunity to SARS-CoV-2 induced by infection and vaccination | Haematologica | Spyridoula Vasileiou Manik Kuvalekar Yovana Velazquez Ayumi Watanabe Mansi Narula | 2023/7/7 |
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses | 2023/11/9 |
